PET/CT Imaging of Differentiated and Medullary Thyroid Carcinoma Using the Novel SSTR-targeting Peptide [F]SiTATE - First Clinical Experiences

Overview

Journal Eur J Nucl Med Mol Imaging

Specialties Biophysics
Nuclear Medicine
Radiology

Date 2024 Oct 15

PMID 39404789

Authors

Sophie C Kunte

Vera Wenter

Johannes Toms

Simon Lindner

Marcus Unterrainer

Friederike Eilsberger

Klaus Jurkschat

Carmen Wangler

Bjorn Wangler

Ralf Schirrmacher

Maximilian W Tiling

Gabriel T Sheikh

Dirk Mehrens

Matthias Brendel

Johannes Rubenthaler

Christoph J Auernhammer

Christine Spitzweg

Lena M Unterrainer

Adrien Holzgreve

Affiliations

Soon will be listed here.

Abstract

Purpose: The novel F-labeled somatostatin receptor (SSTR)-directed radiotracer [F]SiTATE demonstrated promising results for the imaging of various SSTR-expressing tumor types. Although thyroid carcinomas (TC) express SSTR, data on [F]SiTATE PET/CT imaging in TC are lacking. This study explores the use of [F]SiTATE PET/CT in a patient cohort with histologically proven TC.

Methods: As part of a prospective observational study at a single tertiary cancer center, 21 patients with TC (10 medullary (MTC) and 11 differentiated (DTC)) who underwent at least one [F]SiTATE PET/CT were included (37 scans in total). Mean SUV and SUV of tumoral lesions, mean total-tumor-volume (TTV), and whole-body (WB)-SUV and WB-SUV on PET with their standard deviations (SDs) were determined. PET parameters were correlated to clinical parameters including tumor marker levels (thyroglobulin for DTC, calcitonin for MTC).

Results: 89 lesions were included in the analysis. Metastases were localized in the bone, lymph nodes, lung, soft tissue, and thyroid bed. Osseous (31 lesions; SUV 8.6 ± 8.0; SUV 5.8 ± 5.4) and nodal (37 lesions; SUV 8.7 ± 7.8; SUV 5.7 ± 5.4) metastases showed the highest uptake. The MTC disease burden on PET significantly correlated with the calcitonin tumor marker level (e.g., TTV: r = 0.771, r = 0.594, p = 0.002). For DTC, no such correlation was present.

Conclusion: Our data demonstrate high feasibility of [F]SiTATE PET/CT in a small cohort of patients with MTC and DTC. The use of [F]SiTATE may overcome logistical disadvantages of Ga-based tracers and facilitate SSTR-targeted PET/CT imaging of thyroid carcinoma.

References

Baloch Z, Asa S, Barletta J, Ghossein R, Juhlin C, Jung C . Overview of the 2022 WHO Classification of Thyroid Neoplasms. Endocr Pathol. 2022; 33(1):27-63. DOI: 10.1007/s12022-022-09707-3. View

Reubi J, Schar J, Waser B, Wenger S, Heppeler A, Schmitt J . Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000; 27(3):273-82. DOI: 10.1007/s002590050034. View

Kurz S, Zan E, Cordova C, Troxel A, Barbaro M, Silverman J . Evaluation of the SSTR2-targeted Radiopharmaceutical 177Lu-DOTATATE and SSTR2-specific 68Ga-DOTATATE PET as Imaging Biomarker in Patients with Intracranial Meningioma. Clin Cancer Res. 2023; 30(4):680-686. DOI: 10.1158/1078-0432.CCR-23-2533. View

Valerio L, Giani C, Agate L, Molinaro E, Viola D, Bottici V . Prevalence and Risk Factors of Developing Fistula or Organ Perforation in Patients Treated with Lenvatinib for Radioiodine-Refractory Thyroid Cancer. Eur Thyroid J. 2021; 10(5):399-407. PMC: 8406256. DOI: 10.1159/000514182. View

Unterrainer M, Kunte S, Unterrainer L, Holzgreve A, Delker A, Lindner S . Next-generation PET/CT imaging in meningioma-first clinical experiences using the novel SSTR-targeting peptide [F]SiTATE. Eur J Nucl Med Mol Imaging. 2023; 50(11):3390-3399. PMC: 10541820. DOI: 10.1007/s00259-023-06315-z. View

Boy C, Poeppel T, Kotzerke J, Krause B, Amthauer H, Baum R . [Somatostatin receptor PET/CT (SSTR-PET/CT)]. Nuklearmedizin. 2018; 57(1):4-17. DOI: 10.1055/s-0038-1636560. View

Treglia G, Castaldi P, Villani M, Perotti G, de Waure C, Filice A . Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2012; 39(4):569-80. DOI: 10.1007/s00259-011-2031-6. View

Fu H, Huang J, Zhao T, Wang H, Chen Y, Xu W . Fibroblast Activation Protein-Targeted Radioligand Therapy with 177Lu-EB-FAPI for Metastatic Radioiodine-Refractory Thyroid Cancer: First-in-Human, Dose-Escalation Study. Clin Cancer Res. 2023; 29(23):4740-4750. PMC: 10690094. DOI: 10.1158/1078-0432.CCR-23-1983. View

Cabanillas M, McFadden D, Durante C . Thyroid cancer. Lancet. 2016; 388(10061):2783-2795. DOI: 10.1016/S0140-6736(16)30172-6. View

10.

Naswa N, Sharma P, Kc S, Lata S, Kumar R, Malhotra A . Prospective evaluation of 68Ga-DOTA-NOC PET-CT in patients with recurrent medullary thyroid carcinoma: comparison with 18F-FDG PET-CT. Nucl Med Commun. 2012; 33(7):766-74. DOI: 10.1097/MNM.0b013e3283541157. View

11.

Beyer L, Gosewisch A, Lindner S, Volter F, Mittlmeier L, Tiling R . Dosimetry and optimal scan time of [F]SiTATE-PET/CT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2021; 48(11):3571-3581. PMC: 8440281. DOI: 10.1007/s00259-021-05351-x. View

12.

Blok S, Wangler C, Bartenstein P, Jurkschat K, Schirrmacher R, Lindner S . Good practices for the automated production of F-SiFA radiopharmaceuticals. EJNMMI Radiopharm Chem. 2023; 8(1):25. PMC: 10567618. DOI: 10.1186/s41181-023-00215-1. View

13.

Schlumberger M, Leboulleux S . Current practice in patients with differentiated thyroid cancer. Nat Rev Endocrinol. 2020; 17(3):176-188. DOI: 10.1038/s41574-020-00448-z. View

14.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

15.

Gains J, Moroz V, Aldridge M, Wan S, Wheatley K, Laidler J . A phase IIa trial of molecular radiotherapy with 177-lutetium DOTATATE in children with primary refractory or relapsed high-risk neuroblastoma. Eur J Nucl Med Mol Imaging. 2020; 47(10):2348-2357. DOI: 10.1007/s00259-020-04741-x. View

16.

Koehler V, Berg E, Adam P, Weber G, Pfestroff A, Luster M . Real-World Efficacy and Safety of Multi-Tyrosine Kinase Inhibitors in Radioiodine Refractory Thyroid Cancer. Thyroid. 2021; 31(10):1531-1541. DOI: 10.1089/thy.2021.0091. View

17.

Lindner S, Wangler C, Bailey J, Jurkschat K, Bartenstein P, Wangler B . Radiosynthesis of [F]SiFAlin-TATE for clinical neuroendocrine tumor positron emission tomography. Nat Protoc. 2020; 15(12):3827-3843. DOI: 10.1038/s41596-020-00407-y. View

18.

Lindner S, Simmet M, Gildehaus F, Jurkschat K, Wangler C, Wangler B . Automated production of [F]SiTATE on a Scintomics GRP™ platform for PET/CT imaging of neuroendocrine tumors. Nucl Med Biol. 2020; 88-89:86-95. DOI: 10.1016/j.nucmedbio.2020.07.008. View

19.

Ilhan H, Lindner S, Todica A, Cyran C, Tiling R, Auernhammer C . Biodistribution and first clinical results of F-SiFAlin-TATE PET: a novel F-labeled somatostatin analog for imaging of neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2019; 47(4):870-880. DOI: 10.1007/s00259-019-04501-6. View

20.

Ilhan H, Todica A, Lindner S, Boening G, Gosewisch A, Wangler C . First-in-human F-SiFAlin-TATE PET/CT for NET imaging and theranostics. Eur J Nucl Med Mol Imaging. 2019; 46(11):2400-2401. DOI: 10.1007/s00259-019-04448-8. View